Back to News
Market Impact: 0.18
UBS Initiates Coverage of Core Scientific, Inc. - Equity Right at Buy
Source: Nasdaq
Analyst InsightsCompany Fundamentals
UBS initiated coverage of Core Scientific, Inc. Equity Right (OTCPK:CORZR) with a Buy rating on September 23, 2026. The article characterizes the initiation as part of a series of recent analyst actions, but provides no price target, earnings estimates, or other financial details to quantify the investment case.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CORZ0.45
UBS0.00
More News
- Micron’s stock has become a ‘battleground’ as the AI narrative shifts
- This could infrastructure stock has been hit hard of late. UBS says to buy it
- Bernstein reiterates Royal Caribbean stock rating amid Sandals deal
- Why is CoreWeave stock gaining today?
- UBS initiates Hut 8 Mining stock with buy rating on data center growth
- UBS turns bullish on five AI data center stocks
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)